Stay updated with breaking news from Edication Pricing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An influential US drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and bluebird bio for sickle cell disease.
Three organizations on Wednesday said they were suing the US government to block enforcement of a program that gives Medicare the power to negotiate drug prices.
The US Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives Medicare the power to negotiate drug prices with pharmaceutical companies.
Leaders of major insulin makers and pharmacy benefit managers traded blame for the life-saving drug's high price while testifying at a US Senate committee hearing.
Vertex Pharmaceuticals and CRISPR Therapeutics's one-dose gene editing therapy for sickle cell disease would be cost effective if priced at up to $1.9 million, an influential US drug pricing group said on Wednesday.